An Evaluation of Letrozole and Clomiphene Citrate Efficacy as Ovulation Induction Medication in Females with Polycystic Ovarian Condition

Abstract

Polycystic ovarian condition is the most common endocrinopathy in anovulatory infertile females. As a long-established conventional treatment for ovulation induction, clomifene citrate (also known as clomiphene) is still recommended to PCOS patients as their first line of treatment. Indian PCOS women are more prone to have high levels of clomiphene resistance due to the high frequency of insulin resistance . While letrozole has a high potential for ovulation induction, it is an orally active aromatase inhibitor Letrozole may therefore become an efficient substitute for ovulation induction in these females. The current study compares letrozole 2.5 mg and clomiphene citrate 50 mg as the first-line ovulation induction medications in infertile women with PCOS in an observational study setting. The study's target population was 100 infertile women with PCOS who matched at least two of Rotterdam's criteria. To induce ovulation, 50 women were divided into the Clomiphene Citrate group and 50 into the Letrozole class, respectively. Age, infertility length, BMI, follicle count, pregnancy rate, and endometrial thickness were among the variables observed and examined. Compared to the clomiphene citrate class, the letrozole level held better rates of ovulation, mono-follicular growth, mean endometrial thickness, and pregnancy. The study concludes; letrozole might substitute clomiphene as the primary therapy for ovulation induction in infertile PCOS womenfolkPolycystic ovarian condition is the most common endocrinopathy in anovulatory infertile females. As a long-established conventional treatment for ovulation induction, clomifene citrate (also known as clomiphene) is still recommended to PCOS patients as their first line of treatment. Indian PCOS women are more prone to have high levels of clomiphene resistance due to the high frequency of insulin resistance . While letrozole has a high potential for ovulation induction, it is an orally active aromatase inhibitor Letrozole may therefore become an efficient substitute for ovulation induction in these females. The current study compares letrozole 2.5 mg and clomiphene citrate 50 mg as the first-line ovulation induction medications in infertile women with PCOS in an observational study setting. The study's target population was 100 infertile women with PCOS who matched at least two of Rotterdam's criteria. To induce ovulation, 50 women were divided into the Clomiphene Citrate group and 50 into the Letrozole class, respectively. Age, infertility length, BMI, follicle count, pregnancy rate, and endometrial thickness were among the variables observed and examined. Compared to the clomiphene citrate class, the letrozole level held better rates of ovulation, mono-follicular growth, mean endometrial thickness, and pregnancy. The study concludes; letrozole might substitute clomiphene as the primary therapy for ovulation induction in infertile PCOS womenfolkPolycystic ovarian condition is the most common endocrinopathy in anovulatory infertile females. As a long-established conventional treatment for ovulation induction, clomifene citrate (also known as clomiphene) is still recommended to PCOS patients as their first line of treatment. Indian PCOS women are more prone to have high levels of clomiphene resistance due to the high frequency of insulin resistance . While letrozole has a high potential for ovulation induction, it is an orally active aromatase inhibitor Letrozole may therefore become an efficient substitute for ovulation induction in these females. The current study compares letrozole 2.5 mg and clomiphene citrate 50 mg as the first-line ovulation induction medications in infertile women with PCOS in an observational study setting. The study's target population was 100 infertile women with PCOS who matched at least two of Rotterdam's criteria. To induce ovulation, 50 women were divided into the Clomiphene Citrate group and 50 into the Letrozole class, respectively. Age, infertility length, BMI, follicle count, pregnancy rate, and endometrial thickness were among the variables observed and examined. Compared to the clomiphene citrate class, the letrozole level held better rates of ovulation, mono-follicular growth, mean endometrial thickness, and pregnancy. The study concludes; letrozole might substitute clomiphene as the primary therapy for ovulation induction in infertile PCOS womenfolkPolycystic ovarian condition is the most common endocrinopathy in anovulatory infertile females. As a long-established conventional treatment for ovulation induction, clomifene citrate (also known as clomiphene) is still recommended to PCOS patients as their first line of treatment. Indian PCOS women are more prone to have high levels of clomiphene resistance due to the high frequency of insulin resistance . While letrozole has a high potential for ovulation induction, it is an orally active aromatase inhibitor Letrozole may therefore become an efficient substitute for ovulation induction in these females. The current study compares letrozole 2.5 mg and clomiphene citrate 50 mg as the first-line ovulation induction medications in infertile women with PCOS in an observational study setting. The study's target population was 100 infertile women with PCOS who matched at least two of Rotterdam's criteria. To induce ovulation, 50 women were divided into the Clomiphene Citrate group and 50 into the Letrozole class, respectively. Age, infertility length, BMI, follicle count, pregnancy rate, and endometrial thickness were among the variables observed and examined. Compared to the clomiphene citrate class, the letrozole level held better rates of ovulation, mono-follicular growth, mean endometrial thickness, and pregnancy. The study concludes; letrozole might substitute clomiphene as the primary therapy for ovulation induction in infertile PCOS womenfolk.